Drug discontinuation: Enoxaparin Sodium Injection (LOVENOX)
FDA lists 24 presentations as To Be Discontinued. Companies: Sanofi-Aventis U.S. LLC.
- Published by source
- 2026-10-20
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Sanofi-Aventis U.S. LLC
- Products
- Enoxaparin Sodium Injection LOVENOX
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-10-20
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #860 | new | 2026-10-22 | 807f6f500850…bedd1b | 9220e0d3fd05…ec3b76 |
Chain head: #1076 8ad5adc30b9b…88ce20